uniQure Future Growth

Future criteria checks 2/6

uniQure is forecast to grow earnings and revenue by 17.1% and 35.8% per annum respectively while EPS is expected to grow by 21.3% per annum.

Key information

17.1%

Earnings growth rate

21.3%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	35.8%
Future return on equity	n/a
Analyst coverage	Good
Last updated	07 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:UQ1 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	93	-126	-80	-71	10
12/31/2025	41	-141	-53	-83	13
12/31/2024	39	-194	-157	-152	13
9/30/2024	29	-240	-185	-179	N/A
6/30/2024	28	-285	-111	-104	N/A
3/31/2024	19	-297	-135	-128	N/A
12/31/2023	16	-308	-153	-146	N/A
9/30/2023	112	-228	-161	-151	N/A
6/30/2023	112	-187	-251	-239	N/A
3/31/2023	110	-157	-214	-198	N/A
12/31/2022	106	-127	-163	-145	N/A
9/30/2022	61	-125	-154	-137	N/A
6/30/2022	62	-114	-149	-129	N/A
3/31/2022	525	324	286	304	N/A
12/31/2021	524	330	271	288	N/A
9/30/2021	500	321	281	298	N/A
6/30/2021	500	303	292	303	N/A
3/31/2021	38	-139	-154	-143	N/A
12/31/2020	38	-125	-144	-135	N/A
9/30/2020	6	-166	-132	-124	N/A
6/30/2020	5	-136	-120	-111	N/A
3/31/2020	6	-124	-114	-105	N/A
12/31/2019	7	-124	-105	-99	N/A
9/30/2019	6	-105	-96	-91	N/A
6/30/2019	8	-103	-93	-89	N/A
3/31/2019	9	-92	-86	-81	N/A
12/31/2018	11	-83	-80	-76	N/A
9/30/2018	12	-90	-81	-76	N/A
6/30/2018	11	-78	N/A	-71	N/A
3/31/2018	13	-78	N/A	-74	N/A
12/31/2017	13	-79	N/A	-64	N/A
9/30/2017	20	-67	N/A	-62	N/A
6/30/2017	25	-72	N/A	-65	N/A
3/31/2017	24	-71	N/A	-68	N/A
12/31/2016	25	-73	N/A	-72	N/A
9/30/2016	20	-76	N/A	-81	N/A
6/30/2016	16	-90	N/A	-62	N/A
3/31/2016	14	-90	N/A	5	N/A
12/31/2015	11	-82	N/A	7	N/A
9/30/2015	8	-76	N/A	22	N/A
6/30/2015	6	-58	N/A	13	N/A
3/31/2015	5	-45	N/A	-35	N/A
12/31/2014	6	-50	N/A	-37	N/A
9/30/2014	5	-41	N/A	-29	N/A
6/30/2014	6	-42	N/A	-6	N/A
3/31/2014	6	-41	N/A	-7	N/A
12/31/2013	4	-37	N/A	-6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: UQ1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: UQ1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: UQ1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: UQ1's revenue (35.8% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: UQ1's revenue (35.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if UQ1's Return on Equity is forecast to be high in 3 years time

uniQure Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Forecast to breakeven in 2021

No longer forecast to breakeven

Recent updates

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

Third quarter 2024 earnings released: US$0.91 loss per share (vs US$1.88 loss in 3Q 2023)

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of Amt-162 for the Treatment Sod1-ALS

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$1.16 loss per share (vs US$1.44 loss in 2Q 2023)

Uniqure N.V. Announces Executive Changes

Now 22% overvalued

New minor risk - Shareholder dilution

First quarter 2024 earnings released: US$1.36 loss per share (vs US$1.63 loss in 1Q 2023)

uniQure N.V., Annual General Meeting, Jun 18, 2024

New minor risk - Shareholder dilution

Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director

CEO & Executive Director recently sold €163k worth of stock

Full year 2023 earnings released: US$6.47 loss per share (vs US$2.71 loss in FY 2022)

uniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for Amt-191 Gene Therapy for Fabry Disease

Now 25% undervalued after recent price drop

Third quarter 2023 earnings released: US$1.88 loss per share (vs US$1.02 loss in 3Q 2022)

New major risk - Revenue and earnings growth

uniQure N.V. Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

Second quarter 2023 earnings released: US$1.44 loss per share (vs US$0.84 loss in 2Q 2022)

uniQure N.V. Announces Executive Changes

New major risk - Share price stability

First quarter 2023 earnings released: US$1.63 loss per share (vs US$1.00 loss in 1Q 2022)

CEO & Executive Director recently sold €465k worth of stock

Full year 2022 earnings released: US$2.71 loss per share (vs US$7.17 profit in FY 2021)

CEO & Executive Director recently sold €142k worth of stock

uniQure N.V. Highlights Therapeutic Potential of Amt-260 in Refractory Temporal Lobe Epilepsy (Rtle) At Virtual Research & Development Event

Insufficient new directors

Third quarter 2022 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.84 loss per share (vs US$8.68 profit in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

uniQure N.V. Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Chief Operating Officer recently sold €95k worth of stock

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

First quarter 2022 earnings released: US$1.00 loss per share (vs US$0.91 loss in 1Q 2021)

uniQure N.V., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CEO & Executive Director recently sold €152k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease

CEO & Executive Director recently sold €175k worth of stock

Investor sentiment deteriorated over the past week

uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2021 earnings released: US$0.79 loss per share (vs US$1.21 loss in 3Q 2020)

President of Research & Development recently sold €271k worth of stock

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS US$8.68 (vs US$0.96 loss in 2Q 2020)

Independent Non-Executive Chairman Philip Astley-Sparke has left the company

uniQure N.V. (NasdaqGS:QURE) entered into a definitive agreement to acquire Corlieve Therapeutics SAS for €250 million.

Independent Non-Executive Chairman Philip Astley-Sparke has left the company

uniQure N.V. Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

uniQure N.V. Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

Forecast to breakeven in 2021

No longer forecast to breakeven

uniQure N.V. Presents Hope-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Antibodies to Aav5 Vector

First quarter 2021 earnings released: US$0.91 loss per share (vs US$0.63 loss in 1Q 2020)

uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program

CEO, CFO & Executive Director recently sold €152k worth of stock

Full year 2020 earnings released: US$2.81 loss per share (vs US$3.11 loss in FY 2019)

Revenue misses expectations

New 90-day low: €28.63

uniQure N.V. Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

Chief Accounting Officer recently sold €261k worth of stock

New 90-day low: €30.00